Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 10, 2002, Pages 3164-3167

  Wallace Jr , Richard J ^a   Brown Elliott, Barbara A ^a   Crist, Christopher J ^a   Mann, Linda ^a   Wilson, Rebecca W ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GLYCYLCYCLINE TIGECYCLINE; MINOCYCLINE; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

ANTI-BACTERIAL AGENTS; DOXYCYCLINE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; TETRACYCLINE;

EID: 0036783671     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.10.3164-3167.2002     Document Type: Article

References (23)

1. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria
2. Description of Mycobacterium wolinskyi and Mycobacterium goodii, two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: A cooperative study from the International Working Group on Mycobacterial Taxonomy
3. Activities of the glycylcyclines N,N-dimethylglycylamido-minocycline and N,N-dimethylglycylamido-6-demethyl-6-deoxytetracycline against Nocardia spp. and tetracycline-resistant isolates of rapidly growing mycobacteria
4. Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonaelike organisms
5. Mycobacterium abscessus infection in cystic fibrosis
6. Clinical usefulness of amikacin and doxycycline in the treatment of infection due to Mycobacterium fortuitum and Mycobacterium chelonei
7. Mycobacterial lung disease in cystic fibrosis: A prospective study
8. Comparative in vitro activities of tigecycline against aerobic and anaerobic animal and human bite wound pathogens
9. Tetracycline resistance determinants in Mycobacterium and Streptomyces species
10. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria
11. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae
12. Glycylcyclines: A new generation of tetracyclines
13. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis
14. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines
15. In vivo pharmacodynamic activities of two glycylcyclines (tigecycline and WAY 152,288) against various gram-positive and gram-negative bacteria
16. Skin, soft tissue, and bone infections due to Mycobacterium chelonae subspecies chelonae-importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin
17. American Thoracic Society Statement: Diagnosis and treatment of disease caused by nontuberculous mycobacteria
18. Human disease due to Mycobacterium smegmatis
19. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism
20. Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities
21. Mycobacterium immunogenum sp. nov., a novel species related to Mycobacterium abscessus and associated with clinical disease, pseudo-outbreaks, and contaminated metalworking fluids: An international cooperative study on mycobacterial taxonomy